Lifesci Capital Issues Optimistic Outlook for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at Lifesci Capital increased their Q2 2026 earnings per share estimates for shares of Larimar Therapeutics in a research report issued to clients and investors on Friday, May 15th. Lifesci Capital analyst F. Brisebois now forecasts that the company will earn ($0.48) per share for the quarter, up from their prior estimate of ($0.54). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.68) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.80) EPS.

Several other equities research analysts have also recently issued reports on the company. Truist Financial upgraded Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Tuesday, April 21st. Wedbush cut their target price on Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating for the company in a research note on Monday. Wall Street Zen upgraded Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Citigroup upped their target price on Larimar Therapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $16.33.

Larimar Therapeutics Stock Down 9.5%

Shares of NASDAQ:LRMR opened at $3.24 on Tuesday. The stock has a market cap of $336.57 million, a PE ratio of -1.57 and a beta of 0.91. The business has a 50 day moving average of $4.57 and a 200-day moving average of $3.99. Larimar Therapeutics has a 12-month low of $1.80 and a 12-month high of $6.42.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.22.

Insiders Place Their Bets

In other Larimar Therapeutics news, Director James E. Flynn purchased 5,000,000 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $25,000,000.00. Following the acquisition, the director owned 10,622,957 shares in the company, valued at approximately $53,114,785. The trade was a 88.92% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.50% of the company’s stock.

Institutional Trading of Larimar Therapeutics

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in Larimar Therapeutics by 75.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after acquiring an additional 4,376 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Larimar Therapeutics by 33.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 18,248 shares of the company’s stock worth $59,000 after acquiring an additional 4,619 shares during the period. American Century Companies Inc. grew its holdings in Larimar Therapeutics by 7.8% during the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company’s stock worth $200,000 after acquiring an additional 5,001 shares during the period. Sei Investments Co. grew its holdings in Larimar Therapeutics by 54.5% during the 1st quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after acquiring an additional 5,763 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Larimar Therapeutics by 26.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,008 shares of the company’s stock worth $111,000 after acquiring an additional 6,038 shares during the period. 91.92% of the stock is currently owned by institutional investors and hedge funds.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.